BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace


PsychoGenics logo



AI Companies (Drug Discovery)

Neuropsychiatric disorders impact hundreds of millions of patients, many of whom have poor or no treatment options. Yet, despite the enormous human cost and societal burden, there have been almost no new mechanisms to treat major neuropsychiatric disorders in decades as the target-based approach of identifying highly selective targeted compounds has failed to deliver new and improved treatments for central nervous system (CNS) disorders. Instead, we rely on old drugs, some with serious side effects.

Posts Mentioning This Company

PsychoGenics Introduces eCube, an AI-Driven Platform for Drug Discovery in Neuropsychiatric Disorders

PsychoGenics, a prominent player in AI-enabled phenotypic drug discovery and preclinical CRO services, has recently unveiled eCube, an innovative pharmaco-electroencephalography (pharmacoEEG) platform designed to enhance phenotypic drug discovery. By employing machine learning algorithms, eCube has the potential to identify compounds that can penetrate the central nervous system (CNS) and predict …
SHARE Share in Facebook Share in Twitter Share in LinkedIn Send by email